Raymond James Financial’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Raymond James Financial’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$407K	Buy	9,302 +2,122	+30%	+$98.1K	﹤0.01%	4486
2025 Q4	$326K	Buy	+7,180	New	+$318K	﹤0.01%	4519
2025 Q3	–	Sell	-5,474	Closed	-$185K	–	5674
2025 Q2	$185K	Sell	5,474 -3,924	-42%	-$124K	﹤0.01%	4556
2025 Q1	$299K	Sell	9,398 -67,175	-88%	-$2.55M	﹤0.01%	4222
2024 Q4	$2.97M	Buy	+76,573	New	+$3.22M	﹤0.01%	2679

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

USCWA

U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Armis Advisers Atlanta, Georgia $1.09B AUM 22.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Raymond James Financial's GNOM Position: Q1 2026 in Review

Raymond James Financial increased its Global X Genomics & Biotechnology ETF (GNOM) stake by 30% in Q1 2026, buying an estimated $98.1K and bringing the position to 9,302 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #4486.

Raymond James Financial first reported a position in GNOM in Q4 2024 and has held it in 5 quarters since. The position peaked at $2.97M in Q4 2024. 40 funds tracked by Wall St. Rank hold GNOM as of Q1 2026.

Raymond James Financial held 9,302 shares of Global X Genomics & Biotechnology ETF worth $407K as of Q1 2026.
Raymond James Financial bought 2,122 Global X Genomics & Biotechnology ETF shares in Q1 2026, an estimated $98.1K.
Global X Genomics & Biotechnology ETF made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4486 holding.
Raymond James Financial first reported a position in Global X Genomics & Biotechnology ETF in Q4 2024 and has held it in 5 quarters since.
Raymond James Financial's Global X Genomics & Biotechnology ETF position peaked at $2.97M in Q4 2024.
40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.